Are you Dr. Mathis?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 29 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
10630 Little Patuxent Parkway
Suite 209
Columbia, MD 21044Phone+1 410-740-8066Fax+1 410-740-8068- Is this information wrong?
Summary
- Dr. Mitchell Mathis Jr., MD is a psychiatrist in Columbia, Maryland. He is currently licensed to practice medicine in Maryland.
Education & Training
- National Capital ConsortiumResidency, Psychiatry/Family Medicine, 1997 - 2001
- University of California Davis HealthResidency, Family Medicine, 1994 - 1997
- UniforMed Services University of the Health Sciences F. Edward Hebert School of MedicineClass of 1994
Certifications & Licensure
- MD State Medical License 1997 - 2025
- National Board of Physicians and Surgeons Family Medicine
- National Board of Physicians and Surgeons Psychiatry
Publications & Presentations
PubMed
- 1 citationsShortened Positive and Negative Symptom Scale as an Alternate Clinical Endpoint for Acute Schizophrenia Trials: Analysis from the US Food & Drug Administration.Mathangi Gopalakrishnan, Tiffany Farchione, Mitchell Mathis, Hao Zhu, Mehul Mehta, Ramana Uppoor, Islam Younis> ;Psychiatric Research and Clinical Practice. 2021 Jan 1
- 7 citationsAssociation of End Point Definition and Randomized Clinical Trial Duration in Clinical Trials of Schizophrenia Medications.Islam R. Younis, Mathangi Gopalakrishnan, Mitchell V. Mathis, Mehul Mehta, Ramana S. Uppoor, Hao Zhu, Tiffany Farchione> ;JAMA Psychiatry. 2020 Oct 1
- 16 citationsThe Trend of Increasing Placebo Response and Decreasing Treatment Effect in Schizophrenia Trials Continues: An Update From the US Food and Drug AdministrationMathangi Gopalakrishnan, Hao Zhu, Tiffany Farchione, Mitchell V. Mathis, Mehul Mehta, Ramana S. Uppoor, Islam R. Younis> ;The Journal of Clinical Psychiatry. 2020 Mar 3
- Join now to see all
Press Mentions
- The Latest “Breakthrough Therapy”: Expensive New Drugs for Tardive DyskinesiaNovember 15th, 2020
- Allergan Announces Positive Phase 3 ACHIEVE II Trial Results for Ubrogepant Published in the Journal of the American Medical AssociationNovember 23rd, 2019
- Acadia Pharmaceuticals: This Is Not a Pharmaceuticals CompanyJuly 9th, 2018
- Join now to see all